3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
20
atezolizumab
9
Nivolumab
9
Gemcitabine
9
Docetaxel
5
avelumab
4
Mitomycin
4
Carboplatin
4
fludarabine
3
epacadostat
3
enfortumab vedotin
3
Cyclophosphamide
3
vofatamab
2
valrubicin
2
rucaparib
2
pemigatinib
2
durvalumab
2
cabozantinib
2
Standard of Care
2
Sirolimus
2
Radiation
2
Pemetrexed
2
Cisplatin
2
Bevacizumab
2
B701 protein, Human herpesvirus 6
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
trilaciclib
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Transitional Cell
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled